Regulatory consideration of the assessment of biosimilar products
Why this work is in the frame
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Bibliographic record
Abstract
R the expiration of patents for a number of blockbuster biologics has ushered in an era of the subsequent production of biosimilar products, which might contribute to increased access to these products at an affordable price. However, unlike small molecular drugs with clearly and well-defined composition and structure, biosimilar products that are made in or isolated from living systems have much more complex ingredients. Therefore, there is general consensus that the standard methodology for the assessment of bioequivalence is not appropriate for the assessment of biosimilars, which highlights the need of more complex and specified regulation and approval tracks. The EMA has taken the lead in the regulatory approval framework for biosimilar products, and WHO has published guidelines on the evaluation of biosimilars in order to facilitate the global harmonization. Many other countries such as US, Canada, Japan and Korea have also issued their own guidance for evaluating biosimilar products. The basic concepts and main principles of approving biosimilars are similar among various regions, notwithstanding some differences in regard to the scope, the choice of reference product, and the date requirement. The first part of the session is going to review the fundamental differences between small molecular drug and biotechnology medicinal products. The second part is going to focus on the comparison of regulatory requirements in various regions and recommendations regarding global harmonization.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.002 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it